Neurocrine Biosciences, Inc. (NBIX) — Financial statements
Income statement, balance sheet, and cash flow for Neurocrine Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2,861↑21.4% | 2,355↑24.8% | 1,887↑26.8% | 1,489↑31.3% | 1,134 | |
| Cost of Revenue | 52↑53.2% | 34↓14.4% | 40↑71.1% | 23↑62.2% | 14 | |
| Gross Profit | 2,808↑21.0% | 2,321↑25.7% | 1,847↑26.1% | 1,466↑30.9% | 1,119 | |
| Operating Expenses | ||||||
| R&D Expenses | 1,016↑38.9% | 731↑29.4% | 565↑21.8% | 464↑41.4% | 328 | |
| General & Administrative Expenses | 0.00↓100.0% | 816 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 191 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 1,156↑14.8% | 1,007↑13.5% | 888↑17.9% | 753↑29.0% | 583 | |
| Other Expenses | 17↑39.2% | 13↓91.3% | 144 | 0.00↓100.0% | 105 | |
| Operating Expenses | 2,189↑25.0% | 1,751↑9.7% | 1,597↑31.2% | 1,217↑19.7% | 1,017 | |
| Total Costs & Expenses | 2,241↑25.6% | 1,785↑9.1% | 1,636↑32.0% | 1,240↑20.2% | 1,031 | |
| Operating Results | ||||||
| Operating Income | 619↑8.5% | 571↑127.4% | 251↑0.8% | 249↑142.9% | 103 | |
| Depreciation & Amortization | 30↑11.1% | 27↑27.2% | 21↑36.5% | 16↑43.1% | 11 | |
| EBITDA | 667↑4.2% | 640↑53.7% | 416↑57.3% | 265↑91.6% | 138 | |
| EBIT | 637↑3.9% | 613↑55.2% | 395↑58.6% | 249↑95.8% | 127 | |
| Interest & Other Income | ||||||
| Net Interest Income | 90↑353.7% | -36↓673.9% | -5↓212.2% | 4↑115.9% | -26 | |
| Interest Income | 90↓0.8% | 91 | 0.00↓100.0% | 11 | 0.00 | |
| Interest Expense | 0.00↓100.0% | 127↑2652.2% | 5↓35.2% | 7↓72.5% | 26 | |
| Non-Operating Income | -17↑58.7% | -42↑70.7% | -144 | 0.00↑100.0% | -25 | |
| Other Income / Expenses | 86↑202.1% | -85↓204.1% | 81↑331.3% | -35↓3090.9% | -1 | |
| Income Before Tax | 705↑45.1% | 486↑46.3% | 332↑55.3% | 214↑110.9% | 101 | |
| Income Tax Expense | 227↑56.7% | 145↑75.6% | 82↑38.7% | 59↑403.4% | 12 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 479↑40.2% | 341↑36.7% | 250↑61.6% | 155↑72.4% | 90 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 479↑40.2% | 341↑36.7% | 250↑61.6% | 155↑72.4% | 90 | |
| Bottom-Line Net Income | 479↑40.2% | 341↑36.7% | 250↑61.6% | 155↑72.4% | 90 | |
| EPS (Basic) | 4.81↑41.5% | 3.40↑32.8% | 2.56↑59.0% | 1.61↑69.5% | 0.95 | |
| EPS (Diluted) | 4.67↑41.9% | 3.29↑33.2% | 2.47↑58.3% | 1.56↑69.6% | 0.92 | |
| Weighted Average Shares | 100↓0.9% | 100↑2.8% | 98↑2.0% | 96↑1.3% | 95 | |
| Weighted Average Diluted Shares | 103↓1.2% | 104↑2.7% | 101↑2.1% | 99↑1.0% | 98 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.